Stocks Health care BDX
NYSE · Health careBecton Dickinson & Co (BDX)
Becton Dickinson & Co brought in $22.4B of revenue over the twelve months to June 30, 2026, up 13.1% from a year earlier. Net income was $941M, a net margin of 4.2%. Operating cash flow minus capital spending left $2.7B of free cash flow in fiscal 2025. At June 30, 2026 it held $708M in cash against $13.5B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Becton Dickinson & Co
- Net worth
- Becton Dickinson & Co has a market value (market cap) of $51.5B at the latest share price, and shareholders' equity of $24.4B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $21.8B (+8.2% year on year), with net income of $1.7B. Over the 12 months to June 30, 2026: revenue $22.4B, net income $941M.
- Cash flow
- In fiscal 2025 operations brought in $3.4B of cash; after $760M of capital spending, free cash flow was $2.7B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Becton Dickinson & Co's next report was expected around September 28, 2026 and is not on file with the SEC yet.
- Dividend
- Becton Dickinson & Co paid dividends of $4.16 per share in fiscal 2025, a yield of 2.20% at the current price.
What Becton Dickinson & Co does
Becton, Dickinson and Company manufactures and sells medical supplies, laboratory equipment, and diagnostic products. Its offerings include syringes, needles, vascular access devices, and automated diagnostic systems, purchased by hospitals, clinical laboratories, pharmacies, and healthcare workers. Its shares trade on NYSE under the ticker BDX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $21.8B | $1.7B | $5.82 | $2.7B |
| 2024 | $20.2B | $1.7B | $5.86 | $3.1B |
| 2023 | $19.4B | $1.5B | $4.94 | $2.1B |
| 2022 | $18.9B | $1.8B | $5.88 | $1.5B |
| 2021 | $19.1B | $2.1B | $6.85 | $3.5B |
| 2020 | $16.1B | $874M | $2.71 | $2.8B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BDX ranks in Health care
Dividends
Becton Dickinson & Co paid $4.16 per share in fiscal 2025. At the current price that is a yield of 2.20%. It paid out $1.2B in cash dividends, 71% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $4.16 | $1.2B | 71% |
| 2024 | $3.80 | $1.1B | 65% |
| 2023 | $3.64 | $1.1B | 75% |
| 2022 | $3.48 | $1.1B | 61% |
| 2021 | $3.32 | $1B | 50% |
| 2020 | $3.16 | $1B | 117% |
Latest SEC filings
What Becton Dickinson & Co has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 5.4% to $5B versus the same quarter last year; diluted EPS $1.37 versus $2.00.
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- July 22, 2026
- June 29, 2026
- June 29, 2026
- June 4, 2026Delisting notice 25-NSE
- May 29, 2026
- May 22, 2026
What is BDX worth? A DCF from its reported cash flow
Insider trades
What the people running Becton Dickinson & Co did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.3M worth of shares in the last 90 days and bought none on the open market. Most of the selling (65%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 28, 2026 | Feld MichaelEVP, Chief Revenue Officer | Soldpre-planned (10b5-1) | 76 | $14K |
| September 2, 2026 | Roque VitorEVP & Chief Financial Officer | Shares withheld for tax | 190 | - |
| August 26, 2026 | Feld MichaelEVP, Chief Revenue Officer | Soldpre-planned (10b5-1) | 165 | $31.1K |
| August 20, 2026 | Feld MichaelEVP, Chief Revenue Officer | Shares withheld for tax | 1,049 | - |
| August 13, 2026 | Polen Thomas E JrChairman, CEO and President, Director | Exercised options | 43,278 | $7.2M |
| August 13, 2026 | Polen Thomas E JrChairman, CEO and President, Director | Other change | 39,126 | $7.2M |
| August 13, 2026 | Polen Thomas E JrChairman, CEO and President, Director | Soldpre-planned (10b5-1) | 4,152 | $768.1K |
| August 11, 2026 | Goette RolandEVP and President, EMEA | Sold | 2,438 | $440.9K |
Who owns BDX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.51% | April 29, 2026 |
| Vanguard Portfolio Management13G, passive | 5.4% | April 29, 2026 |
| First Eagle Investment Management, LLC13G, passive | 5.1% | August 6, 2026 |
Largest institutional holders
Insiders
25 insiders reported holding 470,376 shares in total, about $88.8M at the last price.
| Holder | Shares |
|---|---|
| Polen Thomas E JrChairman, CEO and President, Director | 110,163 |
| Ring Timothy MDirector | 59,160 |
| Muhsin BilalEVP & President Connected Care | 41,359 |
| Scott Bertram LDirector | 36,763 |
| Jones Christopher Ian MontagueDirector | 24,304 |
| Neal Shana CarolEVP and Chief People Officer | 23,966 |
| DelOrefice ChristopherEVP & Chief Financial Officer | 22,982 |
| Feld MichaelEVP, Chief Revenue Officer | 19,644 |
| Goette RolandEVP and President, EMEA | 14,856 |
| Menziuso PeterEVP and President, BDI | 14,258 |
Questions about BDX
What does Becton Dickinson & Co do?
Becton, Dickinson and Company manufactures and sells medical supplies, laboratory equipment, and diagnostic products. Its offerings include syringes, needles, vascular access devices, and automated diagnostic systems, purchased by hospitals, clinical laboratories, pharmacies, and healthcare workers. Its shares trade on NYSE under the ticker BDX.
What is Becton Dickinson & Co's net worth?
Becton Dickinson & Co has a market value (market cap) of $51.5B at the latest share price, and shareholders' equity of $24.4B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Becton Dickinson & Co profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $941M on revenue of $22.4B, a net margin of 4.2%.
How much revenue does Becton Dickinson & Co make?
Over the twelve months to June 30, 2026 Becton Dickinson & Co reported revenue of $22.4B. That is 13.1% more than a year earlier.
When did Becton Dickinson & Co last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 29, 2026.
When is Becton Dickinson & Co's next earnings report?
Becton Dickinson & Co's next report was expected around September 28, 2026 and is not on file with the SEC yet.
Does Becton Dickinson & Co pay a dividend?
Yes. Becton Dickinson & Co paid dividends of $4.16 per share in fiscal 2025, a yield of 2.20% at the current price.
Similar companies
Compare BDX with
Follow BDX
Get an email when Becton Dickinson & Co files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Becton Dickinson & Co tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.